User login
Key clinical point: Patients with juvenile psoriatic arthritis (JPsA) were more likely to develop uveitis if they were diagnosed with PsA at a younger age or were antinuclear antibody (ANA) positive, with higher disease activity being the only factor significantly associated with the presence of uveitis.
Major finding: Patients with JPsA with vs. without uveitis were younger at JPsA onset (5.3 years vs. 9.3 years) and were more frequently positive for ANA (60.3% vs. 37%; both P < .001). The mean clinical Juvenile Arthritis Disease Activity Score 10 was the only factor significantly associated with the development of uveitis in patients with JPsA (hazard ratio 1.16; P = .025).
Study details: This was an analysis of cross-sectional data from 1,862 patients with JPsA from the National Pediatric Rheumatological Database. Of the patients in the study, 122 developed uveitis.
Disclosures: This study was funded by the Federal Ministry for Research and Education, Deutsche Kinderrheuma-Stiftung, and others. Some of the authors declared receiving honoraria and research grants from several sources.
Source: Walscheid K et al. J Rheumatol. 2022 (Jan 15). Doi: 10.3899/jrheum.210755.
Key clinical point: Patients with juvenile psoriatic arthritis (JPsA) were more likely to develop uveitis if they were diagnosed with PsA at a younger age or were antinuclear antibody (ANA) positive, with higher disease activity being the only factor significantly associated with the presence of uveitis.
Major finding: Patients with JPsA with vs. without uveitis were younger at JPsA onset (5.3 years vs. 9.3 years) and were more frequently positive for ANA (60.3% vs. 37%; both P < .001). The mean clinical Juvenile Arthritis Disease Activity Score 10 was the only factor significantly associated with the development of uveitis in patients with JPsA (hazard ratio 1.16; P = .025).
Study details: This was an analysis of cross-sectional data from 1,862 patients with JPsA from the National Pediatric Rheumatological Database. Of the patients in the study, 122 developed uveitis.
Disclosures: This study was funded by the Federal Ministry for Research and Education, Deutsche Kinderrheuma-Stiftung, and others. Some of the authors declared receiving honoraria and research grants from several sources.
Source: Walscheid K et al. J Rheumatol. 2022 (Jan 15). Doi: 10.3899/jrheum.210755.
Key clinical point: Patients with juvenile psoriatic arthritis (JPsA) were more likely to develop uveitis if they were diagnosed with PsA at a younger age or were antinuclear antibody (ANA) positive, with higher disease activity being the only factor significantly associated with the presence of uveitis.
Major finding: Patients with JPsA with vs. without uveitis were younger at JPsA onset (5.3 years vs. 9.3 years) and were more frequently positive for ANA (60.3% vs. 37%; both P < .001). The mean clinical Juvenile Arthritis Disease Activity Score 10 was the only factor significantly associated with the development of uveitis in patients with JPsA (hazard ratio 1.16; P = .025).
Study details: This was an analysis of cross-sectional data from 1,862 patients with JPsA from the National Pediatric Rheumatological Database. Of the patients in the study, 122 developed uveitis.
Disclosures: This study was funded by the Federal Ministry for Research and Education, Deutsche Kinderrheuma-Stiftung, and others. Some of the authors declared receiving honoraria and research grants from several sources.
Source: Walscheid K et al. J Rheumatol. 2022 (Jan 15). Doi: 10.3899/jrheum.210755.